Northwire Canada EditionSunday, July 12, 2026
Northwire
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
Other

Eupraxia posts 24-week data in high-dose Resolve cohort

EPRX · Price

Executive Summary

  • Eupraxia Pharmaceuticals reported positive six-month (24-week) symptom data from the highest dose cohort of its ongoing Phase 1b/2a Resolve trial for EP-104GI, a treatment for eosinophilic esophagitis (EoE).
  • Patients in the highest-dose cohort (20 by 8 mg) achieved an average reduction of 4.0 points in symptom scores (SDI), exceeding the 3.0-point threshold for clinical remission.
  • The drug demonstrated a strong safety profile with no serious adverse events (SAEs) or cases of oropharyngeal candidiasis across 31 patients and over 220 patient-months of follow-up.

Key Details

  • Symptom Response (Highest Dose Cohort):
    • Cohort 9 (20 injections of 8 mg/site; n=3) showed a mean reduction of 4.0 points in Straumann Dysphagia Index (SDI) scores at 24 weeks.
    • A reduction of 3.0 points is defined as clinical remission.
  • Pooled Subanalysis (Cohorts 4-9, n≥12 injections):
    • 12 Weeks: 59% (13/22) of patients achieved clinical remission.
    • 24 Weeks: 76% (13/17) of patients maintained clinical remission.
    • 52 Weeks: 67% (6/9) of patients maintained clinical remission.
  • New Cohort 8b Findings (6 mg/site):
    • Introduction of larger 19-gauge catheters resolved clogging issues seen at 6 mg/site, allowing for improved drug delivery.
    • Histologic/Symptom Improvements vs. Cohort 8:
      • EoEHSS stage/grade reductions: -0.38/-0.38 (Cohort 8b) vs. -0.08/-0.12 (Cohort 8).
      • SDI reduction: -3.8 (Cohort 8b) vs. -0.3 (Cohort 8).
      • Peak eosinophil reduction: 65.2% (Cohort 8b) vs. 30.6% (Cohort 8).
    • Cohort 8b re-established the dose-response relationship in EoEHSS.
  • Safety and Tolerability:
    • 31 patients treated in Phase 1b/2a; over 220 patient-months of follow-up.
    • Zero Serious Adverse Events (SAEs) reported.
    • Zero cases of oropharyngeal candidiasis (a common side effect of swallowed steroids).
    • No cases of adrenal insufficiency or glucose derangement, including in one diabetic patient.
    • One patient in Cohort 8 was lost to follow-up at six months.
  • Trial Status:
    • Phase 1b/2a is a multicentre, open-label, dose-escalation study.
    • Phase 2b is a randomized, placebo-controlled study currently recruiting for 120 mg (20 by 6 mg) and 160 mg (20 by 8 mg) doses.
    • Top-line data from the Phase 2b portion is expected in Q3 2026.

Notable Quotes

  • "We are very pleased to see such a meaningful symptom response at 24 weeks in the highest dose of the phase 1b/2a portion of the Resolve study... We believe this type of response based on a single administration procedure would represent a compellingly different option for EoE patients." — Dr. James A. Helliwell, CEO
  • "Importantly, the response that we are observing across cohorts 4 to 9 has increased as patients progress through the study through to week 24. We believe this demonstrates the importance of stable, continuous long-term local steroids in tamping down signs of inflammation quickly and acting on fibrosis in the longer term." — Dr. James A. Helliwell, CEO
Read the original news release →

More from Eupraxia Pharmaceuticals Inc